In addition, ulinastatin, a serine protease inhibitor with anti-inflammatory properties (including inhibition of IL-6), previously used in the treatment of acute pancreatitis and sepsis, has been suggested for severe COVID-19 treatment (10); yet its clinical performance and cost-effectiveness remain to be validated in large cohort studies. Here, IL6 is linked to COVID-19.